Vimarsana
Biggest News Aggregation in the World

Johnson Stock News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Johnson Stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Johnson Stock Today - Breaking & Trending Today

Johnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation - Vimarsana News

Johnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation

05.04.2024 - Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of ...

Johnson & Johnson Stock: Is Now the Time to Sell? - Vimarsana News

Johnson & Johnson Stock: Is Now the Time to Sell?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I called JNJ safe before its Kenvue spinoff, but that makes the dividend less safe. The post…

Source: biztoc.com
Johnson & Johnson : Notice of Possible Blackout Period and Regulation BTR Trading Restrictions - Vimarsana News

Johnson & Johnson : Notice of Possible Blackout Period and Regulation BTR Trading Restrictions

Notice of Possible Blackout Period and Regulation BTR Trading Restrictions This blackout notice is being provided in...

Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit - Vimarsana News

Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit

10.07.2023 - Johnson & Johnson (NYSE: JNJ) will participate in the UBS MedTech, Tools and Genomics Summit on Tuesday, August 15th, at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Celine Martin, Company Group Chairman Cardiovascular & ...

Johnson & Johnson Earnings: Steady Results, but Longer-Term Drug Pressures Mounting - Vimarsana News

Johnson & Johnson Earnings: Steady Results, but Longer-Term Drug Pressures Mounting

Patent losses and slower drug launches are weighing on the business.